Shenzhen - Delayed Quote CNY
Chengdu Kanghua Biological Products Co., Ltd. (300841.SZ)
50.34
-0.29
(-0.57%)
At close: April 30 at 3:04:31 PM GMT+8
Key Executives
Amounts are as of -- and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CNY.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Wennian Wu | VP, CFO, Secretary of the Board & Director | -- | -- | 1983 |
| Mr. Huaigong Chen | VP & Quality Manager | -- | -- | 1972 |
| Mr. Wanfeng Sun | Vice President | -- | -- | 1979 |
| Mr. Fu Wang | Vice President | -- | -- | 1969 |
| Mr. Hongbo Wu | President & Non-Independent Director | -- | -- | 1968 |
Chengdu Kanghua Biological Products Co., Ltd.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 620
Description
Chengdu Kanghua Biological Products Co., Ltd. engages in the research, development, production, sale, and technical service of biological products in China. It offers group ACYW135 meningococcal polysaccharide vaccines; and freeze-dried human diploid cell rabies vaccines. The company also develops seasonal influenza vaccines. In addition, it exports its products. The company was founded in 2004 and is based in Chengdu, China.
Corporate Governance
Chengdu Kanghua Biological Products Co., Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
Upcoming Events Information Not Available
Recent Events
May 8, 2024 at 12:00 AM UTC
Ex-Dividend Date